The IPO of Actuate Therapeutics, Inc is likely to generate significant interest due to its focus on developing therapies for difficult-to-treat cancers. The pricing range and insider lock-up period are standard for IPOs, but the company's clinical-stage status and specialized focus may attract investors looking for high-growth opportunities in the biopharmaceutical sector.